---
pmid: '26004684'
title: Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.
authors:
- Han B
- Park D
- Li R
- Xie M
- Owonikoko TK
- Zhang G
- Sica GL
- Ding C
- Zhou J
- Magis AT
- Chen ZG
- Shin DM
- Ramalingam SS
- Khuri FR
- Curran WJ
- Deng X
journal: Cancer Cell
year: '2015'
full_text_available: false
pmcid: PMC4470473
doi: 10.1016/j.ccell.2015.04.010
---

# Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.
**Authors:** Han B, Park D, Li R, Xie M, Owonikoko TK, Zhang G, Sica GL, Ding C, Zhou J, Magis AT, Chen ZG, Shin DM, Ramalingam SS, Khuri FR, Curran WJ, Deng X
**Journal:** Cancer Cell (2015)
**DOI:** [10.1016/j.ccell.2015.04.010](https://doi.org/10.1016/j.ccell.2015.04.010)
**PMC:** [PMC4470473](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470473/)

## Abstract

1. Cancer Cell. 2015 Jun 8;27(6):852-63. doi: 10.1016/j.ccell.2015.04.010. Epub 
2015 May 21.

Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.

Han B(1), Park D(1), Li R(1), Xie M(1), Owonikoko TK(2), Zhang G(2), Sica GL(3), 
Ding C(4), Zhou J(4), Magis AT(5), Chen ZG(2), Shin DM(2), Ramalingam SS(2), 
Khuri FR(2), Curran WJ(1), Deng X(6).

Author information:
(1)Department of Radiation Oncology, Emory University School of Medicine and 
Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA.
(2)Department of Hematology and Medical Oncology, Emory University School of 
Medicine and Winship Cancer Institute of Emory University, Atlanta, GA 30322, 
USA.
(3)Department of Pathology, Emory University School of Medicine and Winship 
Cancer Institute of Emory University, Atlanta, GA 30322, USA.
(4)Chemical Biology Program, Department of Pharmacology and Toxicology, 
University of Texas Medical Branch, Galveston, TX 77555, USA.
(5)Institute for Systems Biology, Seattle, WA 98109, USA.
(6)Department of Radiation Oncology, Emory University School of Medicine and 
Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA. Electronic 
address: xdeng4@emory.edu.

The BH4 domain of Bcl2 is required for its antiapoptotic function, thus 
constituting a promising anticancer target. We identified a small-molecule 
Bcl2-BH4 domain antagonist, BDA-366, that binds BH4 with high affinity and 
selectivity. BDA-366-Bcl2 binding induces conformational change in Bcl2 that 
abrogates its antiapoptotic function, converting it from a survival molecule to 
a cell death inducer. BDA-366 suppresses growth of lung cancer xenografts 
derived from cell lines and patient without significant normal tissue toxicity 
at effective doses. mTOR inhibition upregulates Bcl2 in lung cancer cells and 
tumor tissues from clinical trial patients. Combined BDA-366 and RAD001 
treatment exhibits strong synergy against lung cancer in vivo. Development of 
this Bcl2-BH4 antagonist may provide a strategy to improve lung cancer outcome.

Copyright Â© 2015 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.ccell.2015.04.010
PMCID: PMC4470473
PMID: 26004684 [Indexed for MEDLINE]

Conflict of interest statement: Disclosure of Potential Conflicts of Interest 
The authors disclose no potential conflicts of interest
